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Abstract
Photodynamic therapy (PDT) is an established treatment modality, used mainly for anticancer therapy that relies on the
interaction of photosensitizer, light and oxygen. For the treatment of pathologies in certain anatomical sites, improved
targeting of the photosensitizer is necessary to prevent damage to healthy tissue. We report on a novel dual approach of
targeted PDT (vascular and cellular targeting) utilizing the expression of neuropeptide somatostatin receptor (sst2) on tumor
and neovascular-endothelial cells. We synthesized two conjugates containing the somatostatin analogue [Tyr3]-octreotate
and Chlorin e6 (Ce6): Ce6-K3-[Tyr3]-octreotate (1) and Ce6-[Tyr3]-octreotate-K3-[Tyr3]-octreotate (2). Investigation of the
uptake and photodynamic activity of conjugates in-vitro in human erythroleukemic K562 cells showed that conjugation of
[Tyr3]-octreotate with Ce6 in conjugate 1 enhances uptake (by a factor 2) in cells over-expressing sst2 compared to wildtype cells. Co-treatment with excess free Octreotide abrogated the phototoxicity of conjugate 1 indicative of a specific sst2mediated effect. In contrast conjugate 2 showed no receptor-mediated effect due to its high hydrophobicity. When
compared with un-conjugated Ce6, the PDT activity of conjugate 1 was lower. However, it showed higher photostability
which may compensate for its lower phototoxicity. Intra-vital fluorescence pharmacokinetic studies of conjugate 1 in rat
skin-fold observation chambers transplanted with sst2+ AR42J acinar pancreas tumors showed significantly different uptake
profiles compared to free Ce6. Co-treatment with free Octreotide significantly reduced conjugate uptake in tumor tissue (by
a factor 4) as well as in the chamber neo-vasculature. These results show that conjugate 1 might have potential as an in-vivo
sst2 targeting photosensitizer conjugate.
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such as the abdominal or thoracic cavities, this is not possible and
in circumstances where the selectivity of traditional photosensitizers is insufficient, targeted photosensitizer delivery becomes
essential. A targeted approach employs the utilization of ligands,
which can bind specifically to neovascular endothelium or cellular
markers to target tumor tissue. While antibody-conjugates have
received the most attention [4–7], cellular transformations offer
other potent targets to exploit. Growth factor receptors, hormonal, low-density lipoprotein-, transferrin, glucose, folic acid-, and
insulin- receptors have been investigated as cellular markers for
active photodynamic targeting [8–10]. In addition to the overall
aim of increasing the uptake of photosensitizers in target cells, the
small radius of action of singlet oxygen (0.1–0.2 mm) [11] has lead
investigators to deliver conjugates to specific sites within cells.
Targeting of nuclear receptors is one such example [10].

Introduction
In PDT visible light is used to transfer energy to a
photosensitizer. This leads to the production of cytotoxic
intermediates, such as singlet oxygen or free radicals that result
in cell death and tissue response [1]. With the use of fiber optic
devices and endoscopy, light can be delivered to almost any part of
the body, significantly increasing the applications of PDT. For the
ablation of deep-seated solid tumors, interstitial approaches are
used [2]. PDT is approved as a treatment for neovascular age
related macular degeneration and (pre-) cancerous conditions such
as superficial gastric cancer, Barrett’s esophagus, the palliative
treatment of head and neck cancers, and skin malignancies [3].
The ability to confine photosensitizer activation by restricting
illumination to the tumor allows a certain degree of selectivity.
However, for applications of PDT in complex anatomical sites,

PLOS ONE | www.plosone.org

1

August 2014 | Volume 9 | Issue 8 | e104448

Somatostatin Receptor Targeted Photodynamic Therapy

Extensive research in targeted PDT has shown that there are
several factors that affect the efficiency of in vivo tumor targeting.
The chemical modifications that are necessary for the synthesis
(conjugation of photosensitizer with ligand) may lead to a reduced
affinity of the ligand to its receptor or to a reduced singlet oxygen
quantum yield. In an ideal scenario the photosensitizer and ligand
affinity will be preserved, the receptor would be present on the
surface of tumor cells at high concentrations compared to normal
cells and lead to an internalization process that enhances PDT
efficacy [9].
Based on the development of targeted PDT, the somatostatin
receptor (sst) represents an attractive option for tumor targeting.
Ssts are over-expressed in a large number of human cancers.
Receptor density is high and the distribution is usually homogeneous [12]. Among the 5 sst subtypes, the sst2 predominates
[12,13]. This receptor represents the basis for a number of clinical
applications, e.g. symptomatic therapy with somatostatin analogues. Moreover, for diagnostic purposes, sst scintigraphy is an
important tool for a subgroup of neuroendocrine tumors (NET)
[14]. Radiotherapy with radiolabeled somatostatin analogues is
also extremely promising for patients with gastroenteropancreatic
sst2-positive NET [15,16]. Previous studies have shown that
angiogenic vessels, as well as peri-tumoral vessels express ssts,
which is predominantly sst2 [17–20]. It is accepted that
somatostatin acts locally on tumor growth, either through direct
action on tumor cells and/or through action on peritumoral
vessels [21]. Upregulated ssts in tumors makes the sst an attractive
cellular target, since a photosensitizer-conjugate can be used to
target tumor cells as well as neovasculature. Our aim was to
develop an approach to improve PDT by direct conjugation of
photosensitizer with the synthetic, metabolically stable somatostatin analogue octreotate.
We report on the synthesis and in vitro cytotoxicity of two Ce6somatostatin analogue conjugates: Ce6-K3-[Tyr3]-octreotate (1)
and Ce6-[Tyr3]-octreotate-K3-[Tyr3]-octreotate (2). Their in
vitro quantitative uptake and phototoxicity in sst2+ K562 and
WT cells have been compared with those of un-conjugated Ce6.
Intra-vital in-vivo fluorescence pharmacokinetics of conjugate 1
was determined in rat skin-fold observation chambers transplanted
with sst2+ AR42J pancreatic tumor cells.

Synthesis of Ce6-coupled somatostatin analogues and
characterization (File S1)
The synthesis of Ce-6-coupled somatostatin analogues is
summarized in Schemes S1 and S2 in File S1. Scheme S1 shows
the synthesis of Ce6-K3-[Tyr3]-octreotate (conjugate 1), whereas
Scheme S2 summarizes the synthesis of Ce6-[Tyr3]-octreotate-K3[Tyr3]-octreotate (conjugate 2). The Figure S1 in File S1 shows
the ES-MS and HPLC profiles of conjugates 1 and 2.

Cells Transfection and Culture
Copy DNA of the human sst2 receptor was merged into a
LZRS-lyt2-IRES plasmid background (lyt2 being the mouse CD8
receptor). The calcium precipitation method [29] was used to
transfect non-adherent K562 cells with the LZRS-lyt2-IRES-sst2.
Expression of lyt2 was evaluated by means of FACS analysis using
FITC labeled anti-mouse CD8 antibody (BD PharMingen,
Netherlands), 1:160 diluted in FACS-buffer. Clones were grown
form Lyt2 positive isolated cells. Vital clones were cultured and
tested in time for stability of sst2 receptor expression, by means of
both FACS analysis (using FITC labeled octreotate 200 nM) as
well as sst2 mRNA expression by RT-PCR as previously described
[30]. Clone showing high and stable somatostatin receptor
expression (Fig. 2A) was used in further experiments. K562 cells
were grown in RPMI 1640 containing L-glutamine, 10% heatinactivated FCS, 50 mg/ml penicillin and 50 mg/ml streptomycin,
and were maintained in an incubator at 37uC in an humidified
atmosphere of 5% CO2.

Photophysical properties of the conjugates (File S1)
The partition coefficient, steady-state fluorescence and absorption properties, photobleaching properties, singlet oxygen quantum yield and the pH properties of the conjugates were
determined. The details about used methods are part of File S1
and as described previously [31–37].

Cellular uptake
Stock solutions of Ce6 and Ce6-conjugates (1 mM) were
dissolved in 80% DMSO and were stored in the dark at 220uC.
Before experiments, the solutions were diluted to a concentration
of 0.1 mM in 20% DMSO. K562 sst2+ or WT (36105) in 1 ml
RPMI 1640 serum-free or supplemented with 5% FCS were
incubated with Ce6 or with conjugate (1 mM) for 15 min to 24 h
in the dark at 37uC. After incubation, the cells were centrifuged,
cell pellet dissolved in 2% SDS and fluorescence emission spectra
(lexc = 405 nm) recorded. Photosensitizer concentrations were
calculated in triplicate according to a calibration curve generated
by mixing a known concentration of photosensitizer with a lysated
control samples.

Materials and Methods
In a series of studies on photosensitizer conjugation with
octreotate, we began with the development of 2-[1-Hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH)-octreotate conjugates. We selected HPPH because it is considered as a potent and
promising clinical photosensitizer [22]. However, our preliminary
in vitro studies revealed that the lipophilicity of HPPH dominated
the specific recognition of the conjugate by the sst2 receptor and
led to non-specific uptake (unpublished data). We hypothesized
that coupling photosensitizers that are more hydrophilic would be
a more suitable approach. To test this hypothesis, Chlorin e6 (Ce6)
was selected as a photosensitizer. Ce6 is characterized by rapid
elimination from the body [23–26], high absorption in the red
spectral region and high sensitizing efficacy [26]. Although, Ce6 is
very photolabile [27,28], its high solubility in physiological media
[23,24] overcomes the delivery problems of hydrophobic photosensitizers.
The structures of Ce6 and 2 somatostatin analogue conjugates
of Ce6, used in the present study are shown in Figure 1.
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Membrane binding studies with [125I]-SS14
The binding potency of Ce6-conjugates to sst2 on K562 sst2+
cells was evaluated on cell membrane preparations. The quantification of conjugates binding was determined by competition
binding assay (displacement of [125I]-SS14 binding from sst by
increasing concentrations of unlabeled Octreotide or conjugates)
as described previously [30].

Confocal Microscopy
Confocal fluorescence imaging (LSM 510 Meta (Zeiss, Germany)) was performed using a Plan-apochromat 636/1.4 oil
objective. The subcellular distribution of photosensitizer fluorescence was mapped under 405 nm diode laser excitation in the
lambda mode (539–753 nm).
2
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Figure 1. Structures of Ce6 and its two [Tyr3]-octreotate conjugates. (A) Ce6; (B) [Tyr3]-octreotate motif; (C) Ce6-K3-[Tyr3]-octreotate
(conjugate 1) and (D) Ce6-[Tyr3]-octreotate-K3-[Tyr3]-octreotate (conjugate 2). A tri-lysine linker (K3) was used between Ce6 and [Tyr3]-octreotate
motifs to improve the hydrophilicity of the monomeric conjugate 1. A similar linker was also inserted between the two [Tyr3]-octreotate motifs in the
dimeric analog, conjugate 2.
doi:10.1371/journal.pone.0104448.g001
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Figure 2. (A) Comparison of sst2 mRNA expression in transfected human myeloid K 562 sst2+ and WT cells; (B) Displacement of [125I]-SS14 binding to
membrane preparations of K562 sst2+ cells, by unlabeled Octreotide (&), and by conjugates 1 ( ) and 2 ( ).
doi:10.1371/journal.pone.0104448.g002

and cell autofluorescence were measured by the same microscopic
system. The images were reconstructed in RGB format:
blue represents autofluorescence and green photosensitizerfluorescence.

Image Analysis
The spectra were analyzed as a linear combination of basis
spectra and fitted using a singular value decomposition algorithm.
The image analysis was performed using the Labview 7.1
(National Instruments Corporation). Basis spectra of components

PLOS ONE | www.plosone.org

4

August 2014 | Volume 9 | Issue 8 | e104448

Somatostatin Receptor Targeted Photodynamic Therapy

chamber, for each tissue type, were recorded and weighted
averages were used to determine pharmacokinetics. Values are
presented as mean 6 SE. Tests for significance between groups
are performed using Student’s t test where p,0.05 is deemed
significant.

Phototoxicity
In vitro PDT experiments were performed to determine the
phototoxicity of free Ce6 and conjugates. K562 sst2+ and WT cells
were seeded in L-polylysine-coated (10 mg/ml) 96-well (86103/
well) and 24-well (46104/well) and incubated overnight in 5%
CO2 at 37uC. After 24 hours, cells were treated for 4 h with
photosensitizer (0.01–1 mM) in the absence or presence of excess of
unconjugated Octreotide (1025 M) in serum-free medium. After
incubation, cells were washed. Fresh serum-free medium was
added, and cells were illuminated with 652 nm to a dose from 0.5
to 5 J cm22 at 5 mW.cm22. Thereafter, serum-containing
medium was added and cells were allowed to grow for an
additional 3 days in 5% FCS medium. Toxicity was determined
by: measurement of DNA contents using the bisbenzimide
fluorescent dye (Hoechst 33258, Boehring Diagnostics, CA,
USA) and measurement of mitochondrial dehydrogenase cleavage
of WST-1 reagent (Roche Diagnostics, Germany) [38,39].
Experiments were done in triplicates.

Results
Binding properties of conjugates
The sst2 mRNA expression levels in K562 WT and sst2+ cells
are shown in Fig. 2A. Wt and K562 sst2+ cells did not express
detectable levels of sst1, sst3 and sst5 (data not shown).
When tested each conjugate for its ability to compete with
specific binding of [125I]-SS14 to membrane preparations of K562
sst2+, conjugate 1 was 406 less potent than unlabeled Octreotide
(IC50 of 68 nM vs 1.7 nM, respectively). Conjugate 2 also
competed with specific [125I]-SS14 binding, but with an almost
56 higher potency (14 nM) than conjugate 1. Displacement
curves are shown in Fig. 2B.

In-vivo pharmacokinetics in AR42J tumours in the rat
skin-fold chambers

Photophysical properties of conjugates
In PBS at pH = 7.4 the absorption maximas of both conjugates
revealed the shift to longer wavelength compared to Ce6. The
bathochromic shift of the Q band was most pronounced (659 nm
for Ce6 in conjugate 1 and 661 nm in conjugate 2, compared to
655 nm of un-conjugated Ce6) (Table 1). The maximum of Soret
band was shifted from 402 nm for Ce6 alone, to 405 nm for
conjugate 1 and 2. Soret band broadening increased with the
number of [Tyr3]-octreotate in the conjugate.
When the somatostatin analogue was conjugated with Ce6, the
maximum of fluorescence intensity was red shifted (from 661 nm
for Ce6 alone, to 665 nm for 1 and 2). The fluorescence quantum
yield of Ce6 in neutral pH was similar to conjugates 1 (WF = 0.18
for Ce6 and WF = 0.20 for 1). The fluorescence quantum yield of
conjugate 2 was significantly lower (WF = 0.03).
The singlet oxygen production (WD) determined relative to
WD = 0.64 for Ce6 [37], was found WD = 0.73 for conjugate 1 and
WD = 0.59 for conjugate 2. Although the singlet oxygen production
did not significantly differ between the compounds, un-conjugated
Ce6 showed low photostability. During illumination above
5 J.cm22 no fluorescence intensity was detected, without any
further singlet oxygen production (Figure 3A). In contrast to unconjugated Ce6, conjugates 1 and 2 revealed higher photostability.
With higher irradiation dose (.5 J.cm22), the conjugates continue
to produce singlet oxygen (insert of Figure 3A).

Intra-vital confocal fluorescence imaging was performed in
single sided rat skin-fold chambers transplanted with sst2+ AR42J
acinar pancreas tumors as described previously [40]. The study
was approved by the animal experimental committee of the
Erasmus MC. Chambers were prepared in 12 animals divided into
three groups. Animals were anaesthetized (ketamine (100 mg/kg)
i.p. and xylazine (10 mg/kg) s.c. and AR42J cells (1–3 105 cells)
were inoculated superficially in the facia/sub-cutaneous tissue and
an 18 mm round cover slide was placed and fixed to close the
window. On the surrounding tissue Bactroban was applied to
prevent inflammation and analgesia (Rimadyl Cattle 5 mg/kg)
was administered subcutaneously. Pharmacokinetic experiments
were initiated when tumors were clearly visible and had a
microscopically adequate vascular supply. Solutions of free Ce6
and Conjugate 1 were made by dissolving in 80% DMSO and
diluting with PBS to a final concentration of 5% DMSO. The first
group of animals received Ce6 at a dose of 0.2 mg/kg, the second
group received conjugate 1 at a dose of 0.67 mg/kg such that the
same number of Ce6 molecules were administered to each animal;
(equivalent Ce6 concentration of 2.01161024 M). A third group
of animals was pre-administered with free Octreotide, at a dose of
0.5 mg/kg.

Intra-vitial confocal microscopy, image analysis and
statistics

Effect of pH on properties of Ce6 and Ce6-conjugates

Animals were anesthetized using isoflurane/O2 and autofluorescence images were recorded. Drug was administered intravenously into the tail vein. Fluorescence images were acquired 5 and
20 minutes after conjugate administration after which the animal
was allowed to recover. Subsequent fluorescence images were
acquired under anesthesia at 1, 4, 24, 72 and 96 hrs. Animals were
housed in subdued light conditions. Confocal fluorescence imaging
(LSM 510 Meta (Zeiss, Germany)) was performed using a 406
objective. The distribution of Ce6 fluorescence was mapped under
514 nm laser excitation in the lambda mode (539–753 nm). White
light transmission images were acquired to determine regions of
interest (ROIs) within tumor, normal tissue and tissue vasculature.
Spectra acquired from individual pixels were analyzed as a linear
combination of basis spectra and fitted using a singular value
decomposition algorithm. The fluorescence of Ce6 and conjugate
1 was determined in ROIs. No correction for tissue optical
properties was performed. Three regions of interest in each
PLOS ONE | www.plosone.org

Compared to un-conjugated Ce6, the same spectral features
were observed for both conjugates: the fluorescence emission
maximum was blue shifted with decreasing the pH (Figures S2–S4
in File S1). The titration curves displayed inflection points at
pH 6.71 for un-conjugated Ce6 (Figure S2 in File S1), at pH 5.38
for conjugate 1 (Figure S3 in File S1), and at pH 6.28 for
conjugate 2 (Figure S4 in File S1).

Partition coefficients
Octanol-water partition coefficient increased with the number
of [Tyr3]-octreotate within the conjugate structure (Table 1).
Conjugate 1 showed approximately 56 higher accumulation
within the 1-octanol phase relative to Ce6, reflecting its higher
hydrophobicity compared to Ce6 alone. In contrast, 2 had .6006
higher accumulation in 1-octanol than in buffer and can be
classified as hydrophobic.
5
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Table 1. Photophysical properties of Ce6, conjugate 1 and 2 in PBS.

Photophysical property

Ce6

Conjugate 1

Conjugate 2

DnSoret
abs (nm)

27

32

42

21

21

26

pH = 7.4

DnQ(0:0)
abs (nm) pH = 7.4
lSoret
max (nm)

pH = 7.4

lQ(0,0)
max (nm) pH = 7.4

402

405

405

655

659

661

lfmax (nm) pH = 7.4

661

665

665

WF in PBS pH = 7.4

0.18

0.20

0.03

kblA (x 1022 J21 cm2)

25.69

14.07

22.70

WD in PBS pH = 7.4

0.6460.08

0.7360.02

0.5960.03

pKa

6.7160.0947

5.3860.0615

6.2860.035

0.00560.05

0.67960.04

LogP pH = 7.4
DnSoret
abs

DnQ(0:0)
abs is

2.82060.34
lSoret
max

lQ(0,0)
max

and
the full width at half maximum of the Soret and Q(0,0) absorption band, respectively;
and
are the maxima of the Soret and Q(0,0)
Note:
absorption bands, respectively; lfmax is the maximum of fluorescence band; LogP is the logarithm of partition coefficient; WF is the fluorescence quantum yield and WD is
the singlet oxygen quantum yield, kblA is rate constant of initial absorption bleaching and pKa represents the inflection point of pH titration curve (basis for titration
curve was Fmax/A (lexc)).
doi:10.1371/journal.pone.0104448.t001

J.cm22 with increased inhibition of cell growth with increasing
light dose. This was in contrast to cells preincubated with
conjugate 1, for which the light dose dependent effect was seen
from 3.5 J.cm22. At 5 J.cm22, Ce6 alone results in almost
complete inhibition of cell viability, whereas cells preincubated
with conjugate 1 showed a 50% cell survival.

Phototoxicity
Irradiation of K562 sst2+ cells preincubated with conjugates
caused phototoxicity in the concentration dependent manner
(Figure 3B). While 1 mM concentration of conjugate 1 induced
approximately 50% of cell survival compared to controls cells,
with conjugate 2 only 10% of cell survived after 5 J.cm22
(Figure 3B). Co-treatment of K562 sst2+ cells with unlabeled
Octreotide (to prevent the binding of conjugates to sst2) abolished
the inhibitory effect of both conjugates. However, the decrease in
PDT toxicity after Octreotide co-treatment was more evident for
conjugate 1. In addition, while conjugate 1 did not show any
toxicity in K562 WT cells (with or without Octreotide cotreatment), the PDT activity of conjugate 2 on K562 WT was
comparable with the PDT activity on K562 sst2+ cells. Treatment
of cells with the photosensitizer alone (Ce6 un-conjugated or
conjugates), in the absence of light or light exposure alone, had no
effect on cell growth.

Intracellular Localization
The intracellular localization of un-conjugated Ce6 and
conjugate 1 in K562 sst2+ cells is shown in Figures 4B and 4C.
The comparison of cells treated with Ce6 alone and conjugate
showed a clear difference in the distribution of the fluorescence.
After 15 min incubation with Ce6 in serum-depleted medium, the
fluorescence images revealed the presence of Ce6 in the plasma
membrane. At 4 hours, strong staining of membrane structure
together with perinuclear region was detected (Figure 4B). This
was in contrast to the localization of conjugate 1 for which at
15 min the fluorescence was located in the outer membrane with
some discrete localization pattern within the cytoplasm. The
punctuate localization was maintained for longer incubation
periods, with no evidence of fluorescence in the plasma membrane
(Figure 4C).

Intracellular Uptake
The role of the sst2 expression on cell uptake of the conjugates
and un-conjugated Ce6 (1 mM) is shown in Figure 3C. Of the
conjugates, only conjugate 1 showed specificity of uptake. An
approximately 26 higher concentration was detected in sst2+
compared to WT cells. Enrichment of the medium with the serum
decreased the uptake of conjugates by cells, but without any effect
on the specificity of uptake. K562 sst2+ cells displayed 26 higher
uptake of conjugate 1 compared to WT cells, in both serumenriched and -depleted medium. In contrast no difference in
concentration uptake of conjugate 2 between sst2+ and WT cells
was detected. The same result as for conjugate 2 was observed also
for un-conjugated Ce6.

Fluorescence pharmacokinetics in subcutaneously
implanted AR42J tumors
Figure 5A–C shows a representative example of the AR42J in
the rat chamber immediately prior to pharmacokinetic measurements. A white light image shows vital tumor tissue that is
coincident with an OctreoScan-SPECT/CT fusion image showing
uptake in sst2+ positive cells in-vivo. An immunohistochemical
sst2+ stain shows the microscopic distribution of sst2+ cells
surrounded by subcutaneous facia (normal tissue). The spatial
distribution of pharmacokinetics from conjugate 1 is shown in
Figure 5D–G. Five minutes after administration the conjugate 1
was predominately in the chamber vasculature. At 1 hour and in
particularly 4 hours after administration increased fluorescence
was observed in tumor tissue immediately surrounding the small
vessels in the tumor microvasculature. After 24 hours conjugate 1
was clearing from tumor and normal tissue. Figure 5H–J shows
the fluorescence pharmacokinetics of conjugate 1 in tumor tissue

Comparison of Phototoxicity Induced by Conjugate 1
and Un-conjugated Ce6 on K562 Sst2+ Cell Line
The phototoxicity of K562 sst2+ cells attributed to the 4 h
incubation with conjugate 1 and un-conjugated Ce6 and light
exposure is shown in Figure 4A. Both photosensitizers induced a
PDT effect in a light-dose dependent manner. However, for the
same dose of light, the un-conjugated Ce6 was more potent than
conjugate 1. The un-conjugated Ce6 shows phototoxicity after 0.5
PLOS ONE | www.plosone.org
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Figure 3. (A) Kinetics of fluorescence bleaching of photosensitizers (&) Ce6, ( ) conjugate 1 and ( ) conjugate 2 in PBS under 652 nm irradiation
(the fluorescence emission spectra of photosensitizers have been detected with the excitation wavelength lexc = 405 nm). Insert: Singlet oxygen (1O2)
production by Ce6 and Ce6-conjugates; (B) Conjugates receptor-specificity proliferation of K562 sst2+ and WT cells after PDT (5 J.cm22 light dose with
652 nm irradiation). Different concentrations of conjugates 1 and 2 were incubated with sst2+ and WT cells: (&) in the absence of unlabeled
Octreotide and (%) with Octreotide co-treatment (c = 1025 M). Test of significance between the group of conjugates phototoxicity in absence and in
presence of Octreotide has been performed using Student’s test. In case of conjugate 1 value p,0.005 is deemed significant, whereas for conjugate
2 p,0.05; (C) The effect of the sst2 expression on the uptake of conjugate 1, 2 and un-conjugated Ce6. The photosensitizers (c = 1 mM) were
incubated with K562 cells in serum-free medium (top) and in the medium with 5% FCS (bottom): (&) K562 sst2+, ( ) K562 WT cells.
doi:10.1371/journal.pone.0104448.g003

and in chamber vasculature. The pharmacokinetics of conjugate 1
in tumor tissue were significantly different from free Ce6.
Conjugate 1 fluorescence peaks between 20 and 60 minutes
whereas Ce6 gradually increased over the first 3 days after
administration (Figure 5H). Both drugs were cleared during the
time course of the experiment. Figure 5I shows that co-administration of Octreotide significantly reduced the uptake of conjugate
1 in tumor tissue. Figure 5J shows the uptake of conjugate 1 in
tumor vasculature was also reduced when Octreotide was
administered.

conjugates compared to un-conjugated Ce6. However, as the
authors stated, despite promising results, the direct applicability in
cancer therapy is limited, due to the low expression of insulin
receptors on most hepatoma cells. This shows that while
conjugation enhanced phototoxic properties of conjugate compared to free Ce6, the selectivity of conjugate uptake can be
hampered by low receptor expression.
In the work of Del Governatore [5], several Ce6 molecules were
covalently attached to anti-colon cancer monoclonal antibody
17.1A, in a way that conjugates had either cationic or anionic
charges. Both immunoconjugates showed in vitro selectivity for
antigen-positive target cells with a specificity of uptake (by a factor
of approximately 1.9) that is similar to what we have found in the
present study. Further in vivo biodistribution studies by the same
investigators [4] showed that the anionic immunoconjugate
showed both a higher absolute uptake of Ce6 in tumor tissue
and a superior selectivity for tumor over normal tissue.
It is interesting to consider our finding that conjugate 1 is the
least efficient photosensitizer at equivalent concentration of
incubation and light fluence. There are a number of potential
explanations for the higher efficacy of un-conjugated Ce6 than of
conjugate 1. First, the quantitative uptake of Ce6 into cells may
play an important role in efficacy. Second, as a result of
conjugation, the photochemical reactivity of un-conjugated Ce6
versus conjugate might differ and third, the site of intracellular
localization is different of the photosensitizer and is known to be
an important factor [10]. Our concentration uptake data showed
that for a 4 h incubation period, un-conjugated Ce6 and conjugate
1 are taken up by sst2+ cells equally, (961028 M was found for
both photosensitizers). This means, that the higher PDT activity of
Ce6 on sst2+ cells cannot be related to uptake differences.
To investigate our second hypothesis, the photophysical
properties of each photosensitizer(-conjugate) were determined.
The spectroscopic changes for both conjugates and these were
most significant for conjugate 2 (broadening of the absorption
spectra and decrease in fluorescence quantum yield as a result of
increase hydrophobicity and insolubility in aqueous media). The
quantum yield of 1O2 observed with un-conjugated Ce6 was not
significantly altered by conjugation of [Tyr3]-octreotate molecule
to Ce6. In fact, 1O2 production was higher for conjugate 1
(WD = 0.7360.02) than that for Ce6 (WD = 0.6460.08). Figure 3
also illustrates that conjugate 1 is more photo-stable. This might be
explained by the involvement of peptide in the bleaching process.
Although conjugate 1 has a high quantum yield of 1O2
production, the presence of peptide seems to prevent the attack
of the tetrapyrrole ring. It is known that the presence of
aminoacids, in this case within the conjugate, can influence the
consumption of reactive oxygen species [43,44]. However, the
mechanisms underlying these processes are likely to be complex.
This is illustrated by the fact that conjugate 2 showed a similar rate
of photobleaching to Ce6. Here the spatial conformation of the
amino acids and thus their susceptibility to 1O2 attack may be
different. Clearly, while additional information about the peptide
conformation within conjugates 1 and 2 is required to fully
understand these kinetics of photobleaching, our data show that

Discussion
Tumor cells and tumor vasculature are both potential targets of
PDT. However, the preference of cellular versus vascular targeting
is dependent upon the relative distribution of photosensitizers in
each compartment. This relative distribution is determined by the
pharmacokinetics of the photosensitizer. In most cases effective
PDT relies on the strategic choice of drug-light interval between
the administration of photosensitizer and illumination [8]. In
addition to the passive targeting approach, active targeting of
tumor endothelial and cellular markers has been studied
extensively [8,9]. However, for targeted approaches, either only
vasculature, or only tumor cells have been targeted. A high density
of sst2+ has been reported in neuroendocrine tumors, angiogenic
vessels and peritumoral vessels [17–21]. This makes sst2 an
attractive target for tumor therapy, since it can target both tumor
cells and tumor neovasculature simultaneously [12–21].
Our experiments showed that the conjugation of [Tyr3]octreotate with the Ce6 improves its ability to target cancer cells
over-expressing sst2. However, surprisingly, even though both
conjugates showed receptor binding, specific in vitro targeting was
only confirmed for one of the conjugates we studied. The decrease
of phototoxicity of conjugate 1 on K562 sst2+ cells after Octreotide
co-treatment together with no evidence of phototoxicity in K562
WT cells, can be explained by differences in concentration. A
substantial increase in concentration of conjugate 1 by sst2+ cells
compared to WT cells illustrates the role of sst2 in the uptake of
conjugate 1. This was in contrast to conjugate 2 where although
conjugate 2 was found to be a more potent photosensitizer, no
difference in the intracellular concentration of conjugate 2 was
demonstrated in sst2+ compare to WT cells. Similarly, its PDT
effect on sst2+ cells was not inhibited by Octreotide co-treatment
and showed comparable phototoxicity in WT cells. These results
indicate the absence or a minor role of specific uptake of conjugate
2 by sst2. This result is in contrast to the binding affinity of
conjugate 2 which was found to have a high affinity to sst2. This
discrepancy is likely to be a consequence of the fact that conjugate
2 is highly hydrophobic. Because of that the nonspecific
accumulation within the cell dominated the specific recognition
of conjugate 2 by sst2.
A number of authors have used Ce6 for conjugation with either
tumor specific monoclonal antibodies [4–7], or in peptide
mediated approaches with insulin [41] or transferrin [42].
Akhlynina et al. [41] demonstrated superior phototoxicity of
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Figure 4. (A) PDT effects of un-conjugated Ce6 and conjugate 1 (c = 1 mM) on K562 sst2+ cell viability as a function of light dose. There is a
statistically significant difference between the viability of cells incubated with un-conjugated Ce6 followed by irradiation with different light doses
and the non-irradiated cells (groups of controls) (p,0.005). In case of conjugate 1, only 5 J.cm22 light dose shows the significant difference (p,
0.005) when compare to its control (e.g. non-irradiated cells incubated with conjugate 1); (B) Confocal fluorescence images of un-conjugated Ce6 in
K562 sst2+ cells after 15 min and 4-h incubation in serum-free medium; (C) Confocal fluorescence images of conjugate 1 after 15 min (top left image)
and 4-h incubation (top right image) in serum-free medium. Bottom right image shows conjugate 1 localization 4-h after incubation and its
corresponding transmission image (bottom left).
doi:10.1371/journal.pone.0104448.g004

differences in concentration, photostability and 1O2 generation do
not explain the higher phototoxicity of un-conjugated Ce6
compared to conjugate 1.
Therefore, of the three hypotheses, the later, a localization
difference would appear to play the dominant role. Upon
irradiation, cytotoxic products will be formed at sites where

photosensitizers are localized. Photosensitizers initially located in
lysosomes, kill cells less efficiently than those targeted at the
mitochondria or endoplasmatic reticulum [45]. In our study, we
showed a dramatically different localization pattern for unconjugated Ce6 compared to conjugate 1. Fluorescence of unconjugated Ce6 was present diffusely in cellular membranes. In

Figure 5. (A) AR42J tumor in the skin-fold observation chamber; (B) Corresponding OctreoScan-SPECT/CT fusion image; (C) Immunohistochemical
sst2 stain; (D–G) Conjugate 1 fluorescence/white light transmission fusion images 5 min, 1 h, 4 h and 24 h after conjugate administration
respectively; (H) In-vivo fluorescence pharmacokinetics of Ce6 (m) (n = 3) and conjugate 1 ( ) (n = 4) in AR42J tumor tissue in the rat skin-fold
observation chamber; (I) In-vivo fluorescence pharmacokinetics of conjugate 1 in tumor tissue with (#) and without ( ) the addition of free
Octreotide; (J) In-vivo fluorescence pharmacokinetics of conjugate 1 in the tumor vasculature with (%) and without (&) the addition of free
Octreotide. There is a statistically significant difference between the fluorescence in tumor tissue between the blocked and the unblocked groups
20 min (p = 0.04) and 20 min (p = 0.004) after administration
doi:10.1371/journal.pone.0104448.g005
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contrast, conjugate 1 was sequestered in discrete, intracytoplasmic
compartments. Since conjugate 1 is specifically recognized by the
sst2 receptor it is likely that the sst2 endocytosis pathway [12,13] is
the main mechanism of the internalization of conjugate 1.
Moreover, the highly localized pattern of conjugate accumulation for all of the incubation times shows that conjugate 1 does not
diffuse into other cell compartments. Our data on the spectral
properties of un-conjugated Ce6 and Ce6-conjugates shows
evidence of pH-dependent modifications of photosensitizers in
the physiological relevant pH range. The inflection point at
pH 5.3860.06 of conjugate 1 is well within pH range associated
with the somatostatin receptor endocytosis pathway. A pH as low
as 4.7 has been determined during this vesicular maturation [46].
Changes in the ionization state of molecule might mean it is
difficult for the conjugate to pass the membrane of the endosomal/
lysosomal compartments [47] and thus be trapped within these
organelles. High local concentrations of photosensitizers and their
conjugates are known to lead to the formation of aggregates that
have reduced PDT activity [48]. While the formation of
aggregates in endosomal compartments may represent a significant limitation of our approach an interesting future approach
may be the design of novel light treatment regimens that utilize
fractionated illumination to induce relocalization of the conjugate
from its original localization site and/or its disaggregation during
dark intervals in therapy.
Given the differences in in-vitro results for each conjugate,
conjugate 1 was selected to determine in-vivo pharmacokinetics in
an sst2+ tumor model. Encouragingly the pharmacokinetics of
fluorescence in AR42J tumors showed conjugate 1 exhibited a
receptor mediated uptake that can be abrogated with coadministration of Octreotide. The magnitude of this reduction in
fluorescence with co-treatment with Octreotide is a useful
indicator of the in-vivo selectivity of conjugate 1 in sst2+ tumor
tissue. Between 20 minutes and 4 hours after the administration of
conjugate 1 there was on average .46 less fluorescence after the
administration of Octreotide. This level of selectivity is somewhat
larger than that we found in our in-vitro studies. This method of
assessing selectivity has the advantage that the same type of tissue
is being compared and therefore overcomes differences in tissue
optical properties (blood absorption and differences in scattering)
that are known to influence fluorescence imaging techniques. It is
also important to recognize that Octreotide is not present in excess
since the effective concentration was lower than that of conjugate
1. This may lead to a small underestimate of the selectivity of
conjugate 1 for sst2+ tumor tissue. It is also encouraging that we
observe at least a partial sst2 receptor mediated uptake in the
tumor vasculature that was also reduced by co-administration with
Octreotide. This result illustrates the potential of a dual strategy
targeting sst2+ tumour and neo-vasculature that is known to also
express the sst2 receptor. While the rat-skin fold window chamber
transplanted with sst2+ AR42J acinar pancreas tumors was used to
determine the pharmacokinetics of conjugate 1, we believe that
this model is not suitable to perform PDT toxicity studies, since the

distribution of oxygen and light are important factors. In a
previous study we have shown, that it is possible to simultaneously
monitor the photosensitizer photobleaching, in addition to fluence
(rate), hemoglobin oxygen saturation, and blood volume during
PDT, without interruptions to the therapeutic illumination [49].
Since these parameters are important factors that influence the
outcome of PDT, we aim to incorporate these measurements in
future therapeutic studies in-vivo in orthotopic tumor models.
We are not the first to investigate the use of sst targeted PDT invivo. A group from Montana State University has previously
reported results in which tetrapyrrole based photosensitisers are
conjugated with octreotate-targeting peptides that are being
studied for the application of multi-photon activated PDT
[50,51]. While the results of these pre-clinical studies are
encouraging it should be noted that they have been achieved
using the local infiltration of photosensitizer conjugate. This
administration route was chosen because therapeutic doses could
not be injected i.v. via the mouse tail vein because of the high
viscosity of their photosensitizer conjugate. In the present study we
have chosen to administer conjugates systemically using an i.v
injection because we believe that this administration route has a
significantly greater translational potential.
In summary, our studies have clearly shown the impact of
conjugation on photosensitizer properties. The differences between our conjugates demonstrate the necessity of careful study of
the photochemical and photophysical properties of photosensitizer, when the conjugation is involved. This knowledge is important
not only as a potential predictor of success of a conjugate as a PDT
agent but as we have shown, the physicochemical properties of
conjugates are important factors in the process of internalization
and specificity of cellular uptake. While these initial in-vitro and
in-vivo data are encouraging, there remain questions, which will
only be answered by PDT response studies in-vivo.

Supporting Information
File S1 Synthesis of Ce6-coupled somatostatin analogues and
characterization.
(DOC)
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